Engineered Il 2 Variants - Cancer Science

Relevant Publications

Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model.

Issue Release: 2024

Regulating IL-2 immune signaling function via a core allosteric structural network.

Issue Release: 2024

Regulating IL-2 immune signaling function via a core allosteric structural network.

Issue Release: 2024

Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice.

Issue Release: 2024

Strategies to therapeutically modulate cytokine action.

Issue Release: 2023

Multivalent, asymmetric IL-2-Fc fusions show enhanced selectivity for regulatory T cells.

Issue Release: 2023

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.

Issue Release: 2023

Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles.

Issue Release: 2023

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.

Issue Release: 2023

Overcoming lung cancer immunotherapy resistance by combining non-toxic variants of IL-12 and IL-2.

Issue Release: 2023

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.

Issue Release: 2023

Rethinking Oncologic Treatment Strategies with Interleukin-2.

Issue Release: 2023

Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report.

Issue Release: 2022

A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting.

Issue Release: 2022

Interleukin-2 superkines by computational design.

Issue Release: 2022

A Cryptic Plant Terpene Cyclase Producing Unconventional 18- and 14-Membered Macrocyclic C and C Terpenoids with Immunosuppressive Activity.

Issue Release: 2021

Interleukin-2 therapy of cancer-clinical perspectives.

Issue Release: 2021

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.

Issue Release: 2021

Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins.

Issue Release: 2020

Prokaryotic soluble overexpression and purification of oncostatin M using a fusion approach and genetically engineered E. coli strains.

Issue Release: 2019

How Can Telemedicine Be Effectively Integrated into Cancer Care?

How Can Cancer Treatments Affect Skin Sensitivity?

Can Neuroinflammation Promote Tumor Growth and Metastasis?

What Are the Methods to Achieve Reduced Recovery Time?

Who Should Get Screening Mammography?

What are the Benefits of Anastrozole?

What is Pharmacogenomics?

What are Improper Access Controls?

What are the Challenges in Computational Cancer Biology?

What are the Symptoms of Thymic Tumors?

Engineered Il 2 Variants - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics